This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
3 days in-person. 3 days virtually.
March 20–22, 2023 | Basel, SwitzerlandMarch 28–30, 2023 | Digital

Affivant Sciences GmbH

Profile

Affivant is a Basel, Switzerland based biotech company, part of the Roivant family. Affivant was established with an in-licensed innate immune cell engager from Affimed. We are currently raising Series A financing, to bring our lead molecule through a phase 1a, first-in-human trial. This is a clinically de-risked program (both technology and target) which is near-to-clinic with high potential for success in commercially attractive cancer indications. Different to other NK cell engagers, ICE (R) molecules bind to multiple innate effector cells. The platform has tetravalent binding which brings significant efficacy advantages, and further engineering limits the risk of ADA and general FcR activation. The potential for innate cell engagers represents a great opportunity in T cell nonresponsive indications such as ovarian cancer. In addition to monotherapy development, we are exploring combination potential for AFVT-2101, including combination with exogenous NK cell products, novel cytokine agonism and immunotherapy.